VIRBAGEN® OMEGA 10 MU Recombinant feline interferon-ω (rfeIFN-ω) Vaccines
Virbagen® Omega is Used of Recombinant Feline Interferon Omega (RFeIFN-ω) for Treatment of Skin Diseases and Used to Reduce Mortality and Clinical Signs of Parvovirus in Dogs from One Month of Age
Cat
Dog
PARVOVIRUS NEED NOT BE A DEATH SENTENCE!
Virbagen® Omega contains recombinant omega of feline origin IFN-ω (rFeIFN). Type I interferons are cytokines that act as protein messengers which induce multiple immune pathways in the cell. These include multiple immune pathways in the cell. These include increased production of potent anti-viral proteins and enzymes.
Licensed is to treat Canine Parvovirus, Virbagen® Omega is administered intravenously and is proven to decrease mortality rate when used in conjunction with supportive therapies.
Product Features and Benefits:
Licensed for the treatment of parvovirus in dogs
Mortality in dogs is reduced by 4.4x when using Virbagen® Omega in contamination with supportive therapy rather than supportive therapy alone.
When looking specifically at an unvaccinated population, the use of Virbagen®Omega decreases mortality by 6.4 times.
Reduces clinical signs of parvovirus to facilitate a quicker recovery.
Licensed, also, to treat FeLV and FIV/FeLV co-infected cats where it is proven to:
a) Significantly reduce the clinical signs
b) Decrease overall mortality rate
c) Improve overall quality of life
What is Virbagen®Omega?
Virbagen® Omega is a lyophilisate (freeze dried peelet) and solvent that is made into a suspension for injection. Virbagen® Omega contains the active substance recombinant omega interferon of feline origin (from cats) at 5 MU/ vial or 10 MU/vial. It is used for dogs and cats.
What is Virbagen®Omega used for?
Virbagen® Omega is used to reduce mortality and clinical signs of parvovirus (a highly contagious viral infection of dogs) from one month of age. Virbagen® Omega is also to treat cats infected with FeLV (feline leukemia virus) and/or FIV (feline immunodeficiency virus) , in non-terminal cats from the age of 9 weeks.
Dogs: The suspension should be injected intravenously (into a vein) once daily for 3 consecutive days. The dose is 2.5 MU/kg bodyweight.
Cats: The suspension should be intravenously (into a vein) once daily for 3 consecutive days. The dose is 1 MU/kg bodyweight. Two further 5-day treatments must be carried out at 14 days, and 60 days after the first 5-day course.
How does Virbagen®Omega work?
Virbagen® Omega contains the active substance recombinant omega interferon. Interferons are a family of naturally occuring proteins that are produced in response to viral infections. Virbagen® Omega works by stimulating the immune system to attack the virus. The active substance of Virbagen® Omega, omega interferon, is produced by a method known as 'recombinant technology'. The omega interferon is made by a cell that has received a gene (DNA), which makes it able to produce omega interferon. The replacement omega interferon acts in the same way as naturally produced omega interferon.
How has the effectiveness of Virbagen®Omegabeen studied?
Virbagen® Omega has been studied in dogs (males and females) of at five weeks old that were infected with parvovirus. Virbagen® Omega 2.5 MU/kg was given intravenously for 3 days. The main measure of effectiveness was the mortality rate compared with dogs that had not been treated.
Virbagen® Omega has also been in the treatment of anaemic or non-anaemic cats infected with FeLV and/or FIV, from the age of 9 weeks. The main measure of effectiveness was the mortality rate compared with cats that had been treated and clinical signs after treatment.
What is the risk associated with Virbagen®Omega?
The injection of Virbagen® Omega may cause the following temporary symptoms in dogs and cats:
1 - Hyperthemia (increased temperature, 3-6 hours after injection
2 - Transitory vomiting
3 - Soft faeces to mild diarrhoea, in cats only
4 - Fatigue during the treatment, in cats only
Why has Virbagen®Omega been approved?
The Committee for Medicinal Products for Virbagen®Use (CVMP) agreed that the benefits of Virbagen®Omega are greater than any risks to reduce mortality and clinical signs of parvovirus in dogs from one month of age, and to treat cats infected with FeLV (feline leukemia virus) and/or FIV in non-terminal cats from the age of 9 weeks. They recommended that Virbagen® Omega should be given a marketing authorization. The benefit-risk balance may be found in module 6 of this EPAR.
This website uses cookies necessary for the proper functioning of the site and to facilitate your navigation. You will find more information about cookies, how we use them and how you can control their use by clicking on the following link: Cookies. By continuing your visit to this site, you agree that we use cookies, as specified in our policy.
